|Bid||4.06 x 2300|
|Ask||4.10 x 1000|
|Day's Range||3.83 - 3.98|
|52 Week Range||3.61 - 8.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2018 - Mar 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
NEW YORK, Feb. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Washington ...
Insider buying can be an encouraging signal for potential investors. Insiders at three companies made notable share purchases last week. And two of the insiders featured here are regular acquirers of shares. ...
The president of Opko Health's diagnostics division, which accounts for a large share of the company's revenue, has resigned. Opko, majority owned by Miami billionaire investor Phillip Frost, announced Wednesday that Gregory Henderson has left BioReference Laboratories, the third largest commercial testing lab in the U.S. for physician offices, clinics, hospitals, employers and governmental units. Opko (OPK) acquired the New Jersey-based diagnostics company in August 2015 for $1.5 billion in an all-stock deal.
MIAMI, Jan. 26, 2018-- OPKO Health, Inc., announces that Gregory Henderson, M.D., Ph.D., has resigned from his position as President of BioReference Laboratories, an OPKO Health company and the third largest ...
NEW YORK, NY / ACCESSWIRE / January 17, 2017 / Early gains from the major indexes were erased Tuesday as political concerns weighed down the market's recent rally. The Dow Jones Industrial Average declined ...
MIAMI, Jan. 12, 2018-- OPKO Health, Inc., announces today that GeneDx, Inc., a subsidiary of OPKO’ s BioReference Laboratories, has entered into a research collaboration with the Radboud University Medical ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to OPKO Health, Inc. Here are 5 ETFs with the largest exposure to OPK-US. Comparing the performance and risk of OPKO Health, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis OPKO Health, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of OPKO Health, Inc. – TESARO, Inc., Johnson & Johnson, Abbott Laboratories, Regeneron Pharmaceuticals, Inc., Ardelyx, Inc., Bristol-Myers Squibb Company, Laboratory Corporation of America Holdings, Novelion Therapeutics Inc., Alnylam ... Read more (Read more...)
NEW YORK, NY / ACCESSWIRE / November 29, 2017 / U.S. markets closed at record highs Tuesday as the U.S. moved one stepped closer to a tax reform after a recent Senate vote. The Dow Jones Industrial Average ...
MIAMI, Nov. 27, 2017-- OPKO Health, Inc., announces that the Company has enrolled the first patient in a Phase 2 b dose ranging trial of OPK88004, its orally administered selective androgen receptor modulator, ...
NEW YORK, Nov. 27, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PayPal ...
Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its unaudited financial results for the quarter ended September 30, 2017.
OPKO Health (OPK) posts lackluster Q3 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.
NEW YORK, NY / ACCESSWIRE / November 10, 2017 / U.S. markets record rally stalled on Thursday on concerns of a delay in President Trump's proposed tax plan. The Dow Jones Industrial Average declined 0.43 ...
Opko Health Inc. (NASDAQ:OPK) delivered a sore sight to the Street yesterday with a sharp third quarter miss in earnings that has sent investors scrambling away in the aftermath. However, Cantor analyst Louise Chen makes a confident case for the drug maker's "underappreciated" earnings potential.
Opko Health Inc. (NASDAQ:OPK) reports operating and financial results for the three months ended September 30, 2017.